Objective: Pancreatic cancer (PC) is a highly aggressive malignancy with poor prognosis and high mortality rate. Identifying reliable biomarkers for the early diagnosis and treatment is urgently needed. This study aims to comprehensively evaluate the diagnostic and prognostic value of DUPAN-2 in PC through a meta-analysis.
Methods: We systematically searched PubMed, Embase, and other databases for studies related to DUPAN-2 and its prognostic and diagnostic relevance in PC, covering publications up to August 2024. We used pooled hazard ratios (HRs) to evaluate the prognostic value of DUPAN-2 in PC, the summary receiver operating characteristic (SROC) curve and the area under the curve (AUC) to assess diagnostic performance, while pooled odds ratios (ORs) analyzed associations with clinicopathological features.
Results: A total of 22 studies involving 4765 patients were included in this meta-analysis, with 11 studies focusing on diagnostic analysis, 10 on prognostic analysis, and 3 on clinicopathological features. The diagnostic meta-analysis revealed a pooled sensitivity of 0.63 (95 % CI: 0.56-0.69), a pooled specificity of 0.98 (95 % CI: 0.95-0.99), and an AUC of 0.83 (95 % CI: 0.79-0.86). Subgroup analysis indicated that a DUPAN-2 threshold at 150 U/mL achieved the highest diagnostic performance. The prognostic meta-analysis demonstrated that elevated DUPAN-2 levels were associated with poorer OS (HR = 1.70, 95 % CI: 1.36-2.14) and PFS (HR = 1.33, 95 % CI: 1.14-1.56). Additionally, the clinicopathological features meta-analysis showed that elevated DUPAN-2 levels were associated with vascular invasion (OR = 3.48, 95 % CI: 1.26-9.59), while normalized DUPAN-2 levels were associated with higher resectability (OR = 0.57, 95 % CI: 0.36-0.90) and lower N-stage (OR = 0.39, 95 % CI: 0.24-0.63) CONCLUSION: Serum DUPAN-2 demonstrates significant potential as a biomarker for diagnosis and prognosis in patients with PC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cca.2024.120080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DUPAN-2 in pancreatic cancer: Systematic review and meta-analysis.
Clin Chim Acta
December 2024
Department of Biliary and Pancreatic Surgery, First Hospital of Shanxi Medical University, 85(th) Jiefangnan Road, Yingze District, Taiyuan, Shanxi 030001, China. Electronic address:
Objective: Pancreatic cancer (PC) is a highly aggressive malignancy with poor prognosis and high mortality rate. Identifying reliable biomarkers for the early diagnosis and treatment is urgently needed. This study aims to comprehensively evaluate the diagnostic and prognostic value of DUPAN-2 in PC through a meta-analysis.
View Article and Find Full Text PDFA Case of Cancer of Unknown Primary Presenting with Chylothorax.
Intern Med
August 2024
Department of Internal Medicine, Fukuyama City Hospital, Japan.
A 56-year-old man presented to our hospital with dyspnea on exertion for two months. Bilateral pleural effusions were found, and a close examination revealed a chylothorax, including adenocarcinoma. The primary tumor could not be identified by systemic examination.
View Article and Find Full Text PDFASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level.
Ann Surg Oncol
July 2024
Department of Surgeryof Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.
Ann Surg Oncol
July 2024
Department of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) patients with normal carbohydrate antigen (CA) 19-9 levels can have early-stage cancer or advanced cancer without elevation of CA19-9 level; estimating their malignant potential is difficult. This study investigated the clinical utility of the combined use of preoperative CA 19-9 and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels in patients with PDAC.
Methods: Patients who underwent curative-intent surgery for PDAC between November 2005 and December 2021 were investigated.
Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.
J Clin Oncol
June 2024
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
Article Synopsis
- The study explores how levels of the carbohydrate antigen CA19-9 and a related glycan, DUPAN-2, can aid in diagnosing pancreatic cancer, particularly highlighting differences based on genetic variants in fucosyltransferase (FUT) enzymes.
- It involved analyzing genetic data from 938 individuals to determine how these variants affect serum levels of DUPAN-2 and CA19-9, with findings suggesting improved diagnostic sensitivity for early-stage pancreatic cancer.
- The conclusion emphasizes the potential of combining genetic testing with tumor markers to enhance diagnostic accuracy for pancreatic cancer, showing promising results when using a combination of FUT, CA19-9, and DUPAN-2 tests.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!